Modeling Amyotrophic Lateral Sclerosis With Fibroblasts (FIBRALS)
Modeling of Amyotrophic Lateral Sclerosis Using Patient Fibroblasts to Study Different Form of the Disease.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Maria del Mar Amador, MD
- Phone Number: 33 33142162472
- Email: mariadelmar.amador@aphp.fr
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- CIC Neurosciences
-
Contact:
- Maria del Mar Amador, MD
- Phone Number: 33142162472
- Email: mariadelmar.amador@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria common to all 3 populations:
- adults, both sexes
- with written consent to participate in the study
- affiliated to a social security scheme
ALS patients :
- patients with ALS according to the revised El Escorial criteria :
- with a hereditary form of ALS, defined by the presence of a family history of ALS or by the demonstration of a pathogenic mutation in the patient or
- with a juvenile form of the disease, defined by onset of symptoms at less than 30 years of age or
- with a sporadic form of ALS
Asymptomatic mutation carriers :
- Asymptomatic individuals who carry a mutation causing ALS but have not developed symptoms.
Healthy subjects:
- control individuals, taking into account male/female and close age matching
Exclusion Criteria:
- with a known skin disease (acne, atopic dermatitis, psoriasis, melanoma, skin carcinoma, rosacea, scabies; as referenced on http://dermato-info.fr/), which in the investigator's opinion constitutes a contraindication to skin biopsy
- have a platelet count of less than 75,000/mm3 in a laboratory test less than 3 months old,
- with a proven allergy to lidocaine or prilocaine,
- Pregnant or breast-feeding women, or subjects under guardianship, curatorship or safeguard of justice.
- Patient's condition which, in the opinion of the investigator, is incompatible with skin sampling or participation in the study.
- Participation in a clinical trial (involving a drug) or other interventional research if this interferes with FIBRALS research.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: participants (SLA, healthy controls and asymptomatics)
Patients fulfilling the El Escorial criteria definite ALS or asymptomatics or Healthy controls
|
skin biopsy and blood sampling
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Detection of cytoplasmic TDP-43, TIA1 and/or p62 aggregates in patient fibroblasts
Time Frame: 1 year
|
Detection of cytoplasmic TDP-43, TIA1 and/or p62 aggregates in patient fibroblasts subjected to various cellular stresses by immunofluorescence analysis.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neuromuscular Diseases
- Metabolic Diseases
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Motor Neuron Disease
- Nutritional and Metabolic Diseases
- Amyotrophic Lateral Sclerosis
- Investigative Techniques
- Specimen Handling
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Surgical Procedures, Operative
- Cytological Techniques
- Cytodiagnosis
- Diagnostic Techniques, Surgical
- Biopsy
Other Study ID Numbers
Other Study ID Numbers
- APHP231795
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.